Recombinant Human IFN-alpha 7/IFNA7 Protein, CF

Catalog #: 11079-IF Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
11079-IF-050

Recombinant Human IFN-alpha 7/IFNA7 Protein Bioactivity.

2 Images

All IFN-alpha 7/IFNA7 Proteins and Enzymes

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human IFN-alpha 7/IFNA7 Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED₅₀ for this effect is 1.50-30.0 pg/mL.

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha 7/IFNA7 protein
Cys24-Asp189

Accession #

P01567.1

N-terminal Sequence
Analysis

Cys24

Predicted Molecular Mass

20 kDa

SDS-PAGE

18-22 kDa, under reducing conditions.

Product Datasheets

11079-IF

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

11079-IF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 100 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human IFN-alpha 7/IFNA7 Protein (Catalog # 11079-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED₅₀ for this effect is 1.50‑30.0 pg/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human IFN-alpha 7/IFNA7 Protein (Catalog # 11079-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 18-22 kDa.

Reconstitution Calculator

Background: IFN-alpha 7/IFNA7

Interferons (IFN) are a family of cytokines with potent anti-viral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical‑bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). Mature human IFNA7 shares 59% aa sequence identity with mouse IFNA7. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA7 has been shown to be a strong inducer of IFN-stimulated genes and anti-viral protection (8). Additionally, IFNA7 exhibits moderate anti-viral effects against SARS-CoV-2 (9).

References